Michael Maline is a partner in Goodwin's Technology Companies & Life Sciences Group. He practices corporate and securities law with a particular emphasis on representing clients in public and private capital markets transactions such as IPOs, follow-on offerings and private placements of equity and debt securities. His clients include global investment banks, issuers, venture capital and later stage investors and his experience extends to a variety of industries ranging from life sciences, technology and other growth sectors to media and retail/consumer goods.

Mr. Maline is widely regarded as a leader in the area of alternative financing techniques, such as Confidentially Marketed Public Offerings (“CMPOs”), Registered Direct Offerings (“RDs”), Private Investments in Public Equity (“PIPEs”) and At-the-Market Offerings (“ATMs”). Under his leadership, Goodwin consistently ranks as one of the most active law firms in the United States advising on these transactions. Since 2008, Mr. Maline has completed more than 185 offerings of securities totaling in excess of $7 billion in gross proceeds.

Experience

Erfahrung

工作经历

Mr. Maline regularly counsels investment banks and investment funds on issues related to federal securities law, Financial Industry Regulatory Authority (FINRA) rules, New York Stock Exchange and Nasdaq rules and interpretations, and provides other transaction-related and disclosure-related advice, including advising on underwriting agreement and other forms.

Representative Matters

Repräsentative Angelegenheiten

代表事项

Public Offerings
  • J.P. Morgan Securities LLC and Credit Suisse Securities (USA) LLC., as joint book-running managers in the $125 million follow-on offering for OvaScience, Inc., a life sciences company focused on the discovery, development, and commercialization of new fertility treatments
  • J.P. Morgan Securities LLC and Merrill Lynch, Pierce, Fenner & Smith Incorporated., as joint book-running managers in the $115 million follow-on offering for Intrexon Corporation, a synthetic biology company focused on designing, building and regulating gene programs, which are DNA sequences that consist of key genetic components
  • Piper Jaffray & Co., as sole underwriter in a $190 million follow-on offering for Global Eagle Entertainment Inc., a full service provider of content and Internet connectivity to the airline industry
  • Morgan Stanley & Co. LLC, Citigroup Global Markets Inc., Cowen and Company, LLC and Jefferies LLC, as joint book-running managers in a $162 million secondary public offering by existing shareholders for Horizon Pharma, Inc., a specialty pharmaceutical company targeting therapeutic needs in arthritis, pain and inflammatory diseases
  • Cowen and Company, LLC and Robert W. Baird & Co. Incorporated. as joint book-running managers in the $80 million follow-on offering for Cerus Corporation., a biomedical products company focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety by reducing blood-borne pathogens in donated blood components intended for transfusion
  • JMP Securities LLC., as sole book-runner in a $105 million public offering for Flamel Technologies, S.A.., a specialty pharmaceutical company focused on blending its internally developed drug products with its drug delivery capabilities 
  • J.P. Morgan Securities LLC and Barclays Capital Inc., as joint book-running managers in the $160 million initial public offering for Intrexon Corporation
  • Piper Jaffray & Co. and Stifel, Nicolaus & Company, Incorporated, as joint book-running managers in the approximately $60 million initial public offering for Innocoll AG, a global, commercial-stage, specialty pharmaceutical company that develops and manufactures a range of pharmaceutical products and medical devices using its proprietary collagen-based technologies.
  • Deutsche Bank Securities Inc. and Barclays Capital Inc. as underwriters of three public offerings raising gross proceeds of approximately $400 million for Orient-Express Hotels Ltd., the owners/managers of luxury hotels, restaurants and tourist train properties
  • Jefferies & Company, Inc. as underwriter in a $160 million follow-on equity offering for Solutia Inc., a performance materials and specialty chemicals company
  • J.P. Morgan Securities LLC and Morgan Stanley & Co. LLC, as joint book-running managers in a $87 million follow-on offering for NPS Pharmaceuticals, Inc., a biopharmaceutical company developing therapies for patients with rare diseases worldwide
  • Deutsche Bank Securities Inc. as placement agent in a $600 million registered direct offering for The St. Joe Company, a Florida real estate development and operating company 
  • Cowen and Company, LLC and BMO Capital Markets Corp. as joint book-running managers in the $45 million initial public offering for Regado Biosciences, Inc., a biopharmaceutical company focused on the discovery and development of actively controllable antithrombotic drug systems for cardiovascular indications
  • Deutsche Bank Securities Inc. and Cowen and Company, LLC as placement agents in two registered direct offerings raising gross proceeds of approximately $70 million for Smith & Wesson Holding Corporation, one of the world’s leading manufacturers of firearms 
  • Wells Fargo Securities, LLC and Stifel, Nicolaus & Company, Incorporated, as joint book-runners in a follow-on offering for Zogenix Inc., a pharmaceutical company developing products for the treatment of central nervous system disorders and pain
  • William Blair & Company, LLC and Stifel, Nicolaus & Company, Incorporated, as joint book-runners in two follow-on offerings for Spark Networks, Inc., a global media company with a portfolio of consumer websites that includes JDate®.com, ChristianMingle®.com and SilverSingles®.com
Public Financings
  • JMP Securities LLC and Cowen and Company, LLC., as placement agents in a $150 million issuance of convertible senior notes for Horizon Pharma, Inc.
  • Ladenburg Thalmann & Co. Inc., as placement agent in a $93 million PIPE financing for Paratek Pharmaceuticals, Inc. in connection with its merger with Transcept Pharmaceuticals, Inc. Paratek is a biopharmaceutical company focused on the development, and commercialization of innovative antibiotics.
  • Cowen and Company, LLC as placement agent in a $37.5 million PIPE for Alimera Sciences Inc., a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals.
  • Oppenheimer & Co. Inc., as placement agent in an $18.5 million PIPE transaction for Stereotaxis, Inc., a healthcare company that develops robotic cardiology instrument navigation systems designed to enhance the treatment of arrhythmias and coronary disease.

Recognition

Mr. Maline has been recognized by The Legal 500 U.S. for his work on capital markets equity offerings and featured multiple times as a New York “Super Lawyer” by Thomson Reuters.

In The News

In den Nachrichten

在新闻中

Credentials

Anmeldeinformationen

专业资格

Education

J.D., 1994
Tulane University Law School

(magna cum laude, Order of the Coif)

B.A., 1988
The Johns Hopkins University

Admissions

Bar

New York
Massachusetts

Courts

U.S. District Court for the District of Massachusetts
Get In Touch
In Kontakt kommen
Get In Touch
联系我们
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.
Unsere Kunden verlassen sich auf uns für erstklassige Beratungsdienste, beraten über komplexe Transaktionsarbeiten und High-Stakes-Prozesse. Spezialisiert auf Angelegenheiten der Finanz-, Life-Sciences-, Private-Equity-, Immobilien-und Technologie-Industrie, verwenden wir eine kooperative, interdisziplinäre Ansatz zur Lösung unserer Kunden am schwierigsten Fragen. Um mehr zu erfahren, kontaktieren Sie uns bitte.

客户信赖我们世界一流的咨询服务,希望获得针对复杂事务性工作与高风险诉讼的建议。我们通过协作式、跨领域的工作方法来解决客户最棘手的问题,涵盖金融、生命科学、私募股权、不动产和技术等多个行业。如需更多信息,请与我们联系。

Search Other Lawyers
Suche Andere Rechtsanwälte
搜寻其他律师